Encaleret

New England Journal of Medicine(NEJM) publication of positive encaleret proof-of-concept phase 2b results in patients with autosomal dominant hypocalcemia type 1 (ADH1).
Encaleret is an investigational, orally administered small molecule that selectively antagonizes the calcium sensing receptor (CaSR), targeting ADH1 at its source. If approved, encaleret could be the first therapy specifically indicated for the treatment of ADH1.
Encaleret has received fast track designation by the U.S. FDA and orphan drug designation in the United States and the European Union.